PHOTObiomodulation for REsistant Depression Study: An Open-Label Pilot Trial on Transcranial Photobiomodulation for Treatment-Resistant Depression
Photobiomodulation, Photomedicine, and Laser Surgery · 2026-07 · 44 (7) · 448-455
DOI: 10.1177/25785478261456433 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Photobiomodulation, Photomedicine, and Laser Surgery, online erschienen am 02.06.2026. Verfasst von Dennison Carreiro Monteiro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Pernambuco (UFPE), Recife, Brazil. Hauptthemen laut MEDLINE: Depressive Disorder, Treatment-Resistant, Low-Level Light Therapy. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Head Up SA.
Themen: Depression
Abstract (Originalsprache)
Purposes: To evaluate the acute effects, safety, and tolerability of an open-label whole-brain transcranial photobiomodulation (tPBM) protocol in patients with treatment-resistant depression (TRD).
Methods
This prospective, open-label, single-arm pilot trial enrolled 29 adult outpatients with TRD with moderate-to-severe depressive symptoms (Montgomery–Åsberg Depression Rating Scale [MADRS] score ≥20) in the intention-to-treat analysis. The intervention involved a standardized whole-brain tPBM protocol delivered via a light-emitting diode-based helmet (near-infrared light, 810 nm; 12.8 W), administered in 20-min sessions, three times weekly for 4 weeks (12 sessions). The primary outcome was clinical response at the end of the acute treatment phase (T1), defined as ≥50% reduction in MADRS scores. Safety and tolerability were evaluated throughout.
Results
In total, 22 participants completed treatment (per-protocol, n = 22): MADRS scores decreased significantly from 35.5 ± 6.9 at baseline to 22.9 ± 11.2 post-treatment, reflecting a mean change of −12.5 ± 11.3 points ( p < 0.001). Clinical response was achieved in nine participants (40.9%), and remission in two (9.1%). In the intention-to-treat analysis, response and remission rates were 31.0% and 6.9%, respectively. Fourteen participants (63.6%) reported ≥1 mild-to-moderate adverse event; headache was the most common ( n = 11, 50.0%). No serious adverse events occurred.
Conclusion
A 4-week, whole-brain tPBM protocol was associated with clinically meaningful reductions in the severity of depressive symptoms in patients with TRD and was well tolerated. These findings support the feasibility and potential clinical relevance of whole-brain tPBM as a noninvasive neuromodulation strategy. Larger, randomized, sham-controlled trials are warranted to confirm efficacy and optimize stimulation parameters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Federal University of Pernambuco (UFPE), Recife, Brazil.
- Faculty of Medical Sciences, University of Pernambuco (UPE), Recife, Brazil.
- Monteiro Institute of Neuromodulation (IMONN), Recife, Brazil.
- Virtude Mental Health Network - Virtude Conviver Day Hospital, Recife, Brazil.
ORCID-Profile: Dennison Carreiro Monteiro
Förderung
- Head Up SA
Zitieren
APA
Monteiro, D. C., de Oliveira, E. K., Ramos, C. S., Germoglio, C. M., da Silva, E. C. A., de Paula, R. R., & Amorim, J. K. A. (2026). PHOTObiomodulation for REsistant Depression Study: An Open-Label Pilot Trial on Transcranial Photobiomodulation for Treatment-Resistant Depression. Photobiomodulation, Photomedicine, and Laser Surgery, 44(7), 448-455. https://doi.org/10.1177/25785478261456433
Vancouver
Monteiro DC, de Oliveira EK, Ramos CS, Germoglio CM, da Silva ECA, de Paula RR, et al. PHOTObiomodulation for REsistant Depression Study: An Open-Label Pilot Trial on Transcranial Photobiomodulation for Treatment-Resistant Depression. Photobiomodulation, Photomedicine, and Laser Surgery. 2026;44(7):448-455. doi:10.1177/25785478261456433
BibTeX
@article{Monteiro2026,
author = {Monteiro, Dennison Carreiro and de Oliveira, Emilly Karoline and Ramos, Clarence Silva and Germoglio, Carolina de Moura and da Silva, Emmanuela Coeli Alves and de Paula, Roberta Rodrigues and Amorim, Juliane Karine de Aguiar},
title = {PHOTObiomodulation for REsistant Depression Study: An Open-Label Pilot Trial on Transcranial Photobiomodulation for Treatment-Resistant Depression},
journal = {Photobiomodulation, Photomedicine, and Laser Surgery},
year = {2026},
volume = {44},
number = {7},
pages = {448--455},
doi = {10.1177/25785478261456433}
}
EUVIMED